High blood pressure is the main modifiable risk factor for preventing cardiovascular events in people who have had a stroke or transient ischaemic attack; however, only approximately one in three ...
Wearable device data may help detect and track idiopathic pulmonary arterial hypertension, a rare lung disease, a study ...
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...
Guest writer Genesis “Gigi” Gonzalez says that, while living with PH, there are moments when she wants to ask, "Why did this ...
A wireless implantable device that remotely monitors pulmonary artery pressure offers reliable safety and is linked to a significant reduction in the risk for heart failure-related hospitalisation.
In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...
AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral ...
Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in New Orleans, March 28 to 30. The ...
Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...
AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and ...
Congenital diaphragmatic hernia (CDH) remains one of the most challenging neonatal conditions, associated with high morbidity and mortality due to the ...
Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI (TM) algorithm for cardiac amyloidosis (CA) -- the first and only cleared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results